Word Count. 3990 (excluding abstract, references and tables)
Introduction;
Head & Neck (H&N) Squamous Cell Carcinoma (SCC) is the sixth commonest cancer worldwide accounting for approximately 4% of all tumours (1). Despite changes in behavioural exposure to traditional risk factors for H&N SCC(2, 3), the incidence of oropharyngeal squamous cell carcinoma (OPSCC) has shown a steady rise over recent years (4, 5) . Figures from the Scottish Cancer Registry suggest OPSCC demonstrates the most rapidly rising incidence of any anatomical tumour site, exceeding that of both cutaneous melanoma and adenocarcinoma of oesophagus (6) . In 2009, the International Agency for Research on Cancer (IARC) recognised Human Papillomavirus type 16 (HPV16) to be causal in OPSCC (7) . However, epidemiological evidence from several countries points to marked variations in the extent to which HPV16 is involved in OPSCC (8) (9) (10) (11) .
HPV status has been demonstrated to be an important prognostic biomarker in OPSCC(12, 13) with a hazard ratio for overall survival around 0.4 for systematic reviews of clinical trials (14) .
Understandably calls have been made to standardise the definitions and clarify the best test or combination of tests for accurate diagnosis (15) . Currently, a variety of detection methods are available (16) , each with specific benefits and detractions. Additionally, considerable variation in sensitivity and specificity exists between the tests defining HPV status (17) , such that the utility of some has been questioned.
In the H&N oncology clinic, the introduction of HPV testing is justified in order to provide a more representative prognosis to the patient, and in this context we will investigate the relative efficiency of various tests in predicting survival. Another important application of widespread HPV testing is to facilitate recruitment into clinical trials. New trials are now being developed in order to exploit the evident contrast in biology of HPV positive cases compared with conventional smoking and alcohol derived HNSCC. Where de-escalation of therapy is the motivation behind a trial, the hazards to patient safety of inaccurately assigning HPV negative tumours to an HPV positive category are clear. We hypothesise that a "gold standard" test, i.e. most reliable way to detect a biologically relevant HPV infection (18) , is detection of viral mRNA expression carried out using quantitative PCR (qPCR) techniques on fresh-frozen derived samples. Whilst this gold standard may prove valuable in a research setting, it would be logistically difficult to introduce into a routine pathology service where diagnostic algorithms are based on the assessment of FFPE tissue. Against this standard we will therefore compare the prognostic ability, and sensitivity/specificity of seven other detection methods or combinations:p16 immunohistochemistry (p16 IHC); high risk HPV in situ hybridisation (HR HPV ISH); p16 IHC / HR HPV ISH combination; DNA qPCR; p16 IHC / DNA qPCR combination; RNAqPCR, and p16 IHC / RNA qPCR combination.
The analysis of OPSCC cases with individual diagnostic tests is not new, application of a comprehensive diagnostic test panel to OPSCC samples is novel and offers to define the standard for HPV positive OPSCC diagnostic testing. Additionally, this research will provide data clarifying the role of HPV16 from a cohort of OPSCC from the United Kingdom, a region for which no published prognostic data currently exists. Tissue samples included fresh frozen tumour specimens (stored at -80°C; n=100) and formalinfixed paraffin-embedded (FFPE) tissue blocks (n=97). Case notes, electronic patient records, pathology reports and the results of a United Kingdom Office of National Statistics (ONS) database search were reviewed to collate demographic details (age at diagnosis, gender, subsite of tumour, history of tobacco smoking, alcohol consumption and nodal stage) and clinical outcomes: disease specific survival (DSS) and overall survival (OS). All patients from whom samples were derived received surgery, and where necessary adjuvant radiotherapy/chemoradiotherapy.
Materials and methods

Patients
Tissue microarray preparation
Tissue microarrays (TMAs) were constructed from formalin-fixed paraffin-embedded (FFPE) tissue blocks of OPSCC using a manual tissue arrayer (MTA-I, Beecher Instruments, USA), as previously described(20). Briefly, haematoxylin and eosin (H&E) stained sections were used to identify areas of tumour and normal mucosa in the donor block. Three tumour cores and one matched normal mucosal core (height 4mm, diameter 0.6mm) were transferred from the donor block to the recipient block employing a predetermined asymmetrical distribution. H&E stained sections of the TMAs were examined to confirm accurate sampling.
DNA/RNA extraction & cDNA synthesis
The AllPrep DNA/RNA Mini Kit (Qiagen ® ) was used to purify genomic DNA and total RNA simultaneously from fresh frozen tissue samples (2 mm 3 ). All tissue preparation was conducted in a Class II biological safety cabinet with new sterile disposable consumables for each specimen to avoid cross-contamination. An in-column RNase-Free DNase (Qiagen ® ) treatment was incorporated in the RNA extraction protocol to eliminate DNA carry over in the RNA preparations. The purified DNA and RNA samples were quantified by spectrophotometry using NanoDropTM 1000 (Thermo Fischer Scientific). 500-600ng of the total RNA was used for complimentary DNA (cDNA) synthesis using QuantiTect Reverse Transcription Kit (Qiagen ® ). This process included a further genomic DNA elimination step prior to reverse transcription. As a final quality control step, cDNA samples were amplified using primers for two microsatellites at 9p21 and 17p13 loci (21) to ensure an absence of genomic DNA contamination, which was confirmed in all cases. 
Interpretation of HPV tests
The p16 IHC and high risk HPV ISH tests were assessed independently by two H&N pathologists using a binary classification (positive vs. negative). The results were collated and discordant scores were resolved at a meeting between the pathologists to establish a consensus interpretation.
Statistical Analysis
Kaplan-Meier estimates were used to demonstrate both DSS and OS by HPV status as defined by our gold standard, where only those positive in duplicate runs of RNA qPCR were deemed as reliably diagnosed HPV16 driven OPSCC. The Chi-square and Kruskal-Wallis tests were used for comparison of demographic and tumour specific features between periods of sample collection and HPV positive and negative subgroups. Kaplan-Meier estimates and sensitivity and specificity of seven alternative tests (p16 IHC; HR HPV ISH; DNA qPCR; RNA qPCR and combined analysis tests: p16 IHC/HR HPV ISH; p16 IHC/DNA qPCR; and p16 IHC/RNA qPCR) were carried out. The log-rank (Mantel-Cox) test was used for comparison between survival curves according to each of the detection methods. DSS was defined as death from or due to OPSCC, and OS was defined as death from any cause. Both DSS and OS were calculated at thirty-six (36) months follow up beyond the date of initial diagnosis.
DNA and RNA quality was assessed by a Kruskal-Wallis test of the ΔCT of the relevant reference gene (RNase P for DNA qPCR and β Actin for RNA qPCR) to ensure that era of collection did not impact upon detection.
Results:
Cohort characteristics (Table2)
The characteristics of the overall group and comparisons between the three periods of collection are seen in Table 2 . The numbers of cases collected and the clinical and demographic characteristics showed no significant differences with respect to era of collection.
Availability for testing, sample quality and consistency between repeats.
DNA and RNA qPCR
98/108 (91%) and 95/108 (88%) of samples were evaluable for HPV status by DNA and RNA qPCR respectively, with all samples providing analysable results. The cycles to reach threshold (CT) for relevant reference genes (in both RNA and DNA analysis) showed no trend for deterioration by year of sample collection. Therefore we established that there was no conclusive evidence of DNA or RNA degradation over time. Tumour cell proportion within fresh frozen samples was estimated at greater than 50% for all samples and greater than 80% for two thirds of samples analysed. HPV status (Table 3) The HPV16 status within each time period, and the overall total, is expressed as a trend in Table 3 . The percentage of cases attributable to HPV16 by RNA qPCR increased from 14% to 57% in the period (P=0.001). Compared with this standard, the sensitivity of the seven tests and combinations ranged from 88% to 97% and the specificity from 82% to 100% (Table 3) (Table 4) The HPV16 positive group were younger than the HPV16 negative group (mean 53.3 vs. 60.8 yrs, p=0.003). Patient ages fitted in a normal distribution (1-sample Kolmogorov-Smirnov test, p=0.997) and, significantly, the modest 7.5 yrs difference seen between mean ages exceeded the 6.8 yrs difference seen between the median ages. The other notable clinical characteristic correlating with HPV status was smoking history. Of the 82 patients for whom reliable smoking history could be determined, the non-smokers and those smoking <20 pack years were more common in the HPV16 positive group (Pearson's chi square, p=0.007). There were no significant differences between the groups in gender, tumour site, cervical lymph node stage or alcohol consumption.
TMA: P16 IHC & HR HPV ISH
HPV16 testing methods as prognostic biomarkers: survival analysis (Table 5) Kaplan-Meier survival curves using the assigned gold standard RNA qPCR test showed a significant prognostic benefit for OS (P= 0.003) and DSS (P=0.005) (Figures 1 and 2) . Kaplan-Meier estimates of mean survival for the other tests are shown in Table 5 . Although very similar to the gold standard RNA qPCR outcome measures, the test combination conferring greatest prognostic significance for both disease specific and overall survival was p16 IHC/ DNA qPCR (OS, p=0.002 and DSS, p=0.005). The least satisfactory tests in this regard were the sole use of p16 IHC or HR HPV ISH, and also the combination of both. Although remaining statistically significant, the differences in OS (p=0.021, 0.011 & 0.016 respectively) vary by an order of magnitude by comparison with the gold standard. All tests using target amplification of DNA and RNA, performed relatively well in differentiating survival outcomes for both OS and DSS, although it is important to note that DNA qPCR lacked specificity (87%).
Discussion
This study reports the first incidence data for HPV16 in OPSCC with outcome data in a United Kingdom cohort. The proportion of HPV mediated OPSCC cases has increased from 14% to 57% between 1998 and 2009, reflecting known trends seen in other developed countries (11, 14) . As IHC will identify tumours with excess p16 protein due to both the effects of viral E7 protein but also through, as yet unexplained, non HPV-mediated mechanisms (27) . To improve specificity as a test, p16 IHC can be combined with a test for HPV DNA (by PCR or ISH), allowing classification into one of four groups (28) If the calls for inclusion of OPSCC patients into appropriately designed and stratified clinical trials are to be met (14, 15, 29) , then it is vital that accurate classification of HPV status be made prior to enrolment, and with a validated, clinically appropriate test. This is now more than a theoretical problem, as several trials focussed around the de-escalation of treatment to HPV positive groups and in early phase trials of HPV directed agents and immunotherapy have recently opened. Our data suggests that HPV16 status determination with the p16 IHC/DNA qPCR combination test offers a valuable alternative to RNA analysis, with excellent prognostic value and 97% sensitivity / 94% specificity. As a potential alternative with less logistic constraints in routine pathology practice, the combination of p16 IHC/ HR HPV ISH is worthy of consideration, consistent with the diagnostic algorithms suggested by Westra et. al. (30) . In our data, specificity for p16 IHC/ HR HPV ISH, albeit with a HPV high risk cocktail probe rather than a type specific probe, was maintained (90%) but at a cost to sensitivity (88%) that may be deemed undesirable. In routine clinical practice, this compromise may be acceptable, acknowledging that under-representation of HPV positive cases will generally have less serious consequences. Clinical trials in HNSCC frequently struggle to adequately recruit, and in those focussing within one anatomical sub-site, this difficulty may be exaggerated. In order to maximise sensitivity i.e. potential recruitment whilst maintaining specificity i.e. patient safety, the choice of satisfactory test is more limited. Faced with the potential "loss" of approximately 10% of eligible patients using p16 IHC/ HR HPV ISH, the benefits to sensitivity of employing DNA or RNA PCR assays appear to easily balance the additional logistic costs.
With respect to survival, this research reinforces previously reported favourable outcomes for individuals with HPV positive tumours (12, 14, 31, 32) , as demonstrated by both improved DSS and OS. It is apparent that, with the exception of p16 IHC or HR HPV ISH in isolation, most of the other assays available provide a reasonable prognostic guide.
The additional prognostic value of combining HPV16 and smoking history has not been undertaken as the number of non-smokers in this study is small . Hence, further division of the cohorts would preclude meaningful statistical analysis. We speculate that adding smoking data adds accuracy to some other published HPV typing methods that have proven inaccuracies (e.g. P16IHC) as nonsmoking will doubtless be strongly correlated with HPV-16 positive category.
The data presented highlights that the significant recent changes in aetiology amongst OPSCC cases seen in other nations are also present in the United Kingdom. It is thought that the improved survival seen in younger patients will result in an increasing and potentially unnecessary burden of late toxicities arising from combined modality therapy. In addition, data such as these may be helpful in gaining a United Kingdom perspective for decision making surrounding prophylactic vaccination of young males against HR HPV (including HPV16) in addition to females. We show mean age at diagnosis for HPV positive cases to be midway through the 6 th decade, in keeping with other authors (33) . Although the natural history of HPV infection in the oral cavity is, as yet, unclear (34) , any benefits of an introduction of vaccination of boys prior to the age of first sexual contact (12-13 years) may be realised only after 30-35 years.
In conclusion, we present a rigorous analysis of diagnostic tests, judging their value against the most clinically relevant demands of diagnostic accuracy and prognostic relevance. It is hoped that the design of forthcoming clinical trials, aimed at both de-escalating therapy in HPV mediated OPSCC and perhaps intensifying therapy for HPV negative cases, will be informed by these results.
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